Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes uncontrolled on insulin glargine U100

被引：0
|
作者：
Meneghini, L. F. [1 ]
Jaeckel, E. [2 ]
Leiter, L. A. [3 ]
Lingvay, I. [1 ]
Harvey, J. N. [4 ]
Begtrup, K. [5 ]
Chandarana, K. [5 ]
Vilsboll, T. [6 ,7 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Hannover Med Sch, Hannover, Germany
[3] Univ Toronto, Toronto, ON, Canada
[4] Bangor Univ, Wrexham, Wales
[5] Novo Nordisk AS, Soborg, Denmark
[6] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[7] Gentofte Univ Hosp, Ctr Diabet Res, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
671
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [1] Converting to Insulin Degludec/Liraglutide (IDegLira) Is Efficacious Regardless of Pretrial Insulin Dose in Patients with Type 2 Diabetes (T2D) Uncontrolled on Insulin Glargine U100 (IGlar)
    Meneghini, Luigi F.
    Jaeckel, Elmar
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Harvey, John N.
    Begtrup, Kamilla
    Chandarana, Keval
    Vilsboll, Tina
    DIABETES, 2017, 66 : A289 - A289
  • [2] Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
    Meneghini, L.
    Doshi, A.
    Gouet, D.
    Vilsboll, T.
    Begtrup, K.
    Orsy, P.
    Ranthe, M. F.
    Lingvay, I.
    DIABETIC MEDICINE, 2020, 37 (02) : 267 - 276
  • [3] Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes
    Philis-Tsimikas, Athena
    Aroda, Vanita R.
    De Block, Christophe
    Billings, Liana K.
    Liebl, Andreas
    Sivarathinasami, Ramsathish
    D'Cruz, John M.
    Lingvay, Ildiko
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024, 18 (03): : 653 - 659
  • [4] Safe and effective blood glucose lowering with IDegLira in elderly patients with type 2 diabetes uncontrolled on Oral Antidiabetic Drugs (OADs) and/or insulin glargine U100
    Liebl, A.
    Sorli, C. H.
    Linjawi, S.
    Abrahamsen, T. J.
    Lehmann, L.
    Lingvay, I.
    DIABETOLOGIA, 2016, 59 : S402 - S402
  • [5] Effect of insulin degludec U100 vs insulin glargine U100 on time in range in patients with type 2 diabetes at risk of hypoglycaemia
    Goldenberg, R.
    Aroda, V. R.
    Billings, L. K.
    Christiansen, A. S. L.
    Donatsky, A. M.
    Rizi, E. Parvaresh
    Podgorski, G.
    Raslova, K.
    Klonoff, D. C.
    Bergenstal, R. M.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S318 - S319
  • [6] Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes
    Galindo, Rodolfo J.
    Pasquel, Francisco J.
    Vellanki, Priyathama
    Alicic, Radica
    Lam, David W.
    Fayfman, Maya
    Migdal, Alexandra L.
    Davis, Georgia M.
    Cardona, Saumeth
    Urrutia, Maria A.
    Perez-Guzman, Citlalli
    Zamudio-Coronado, Karla Walkiria
    Peng, Limin
    Tuttle, Katherine R.
    Umpierrez, Guillermo E.
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 42 - 49
  • [7] Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes The SWITCH 2 Randomized Clinical Trial
    Wysham, Carol
    Bhargava, Anuj
    Chaykin, Louis
    de la Rosa, Raymond
    Handelsman, Yehuda
    Troelsen, Lone N.
    Kvist, Kajsa
    Norwood, Paul
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (01): : 45 - 56
  • [8] A Randomized Controlled Trial Comparing Insulin Degludec U100 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients with Type 2 Diabetes: Degludec Hospital Trial
    Galindo, Rodolfo J.
    Pasquel, Francisco J.
    Vellanki, Priyathama
    Alicic, Radica Z.
    Lam, David W.
    Fayfman, Maya
    Migdal, Alexandra
    Urrutia, Maria A.
    Davis, Georgia
    Cardona, Saumeth
    Zamudio, Karla W.
    Albury, Bonnie S.
    Perez-Guzman, Mireya C.
    Peng, Limin
    Umpierrez, Guillermo E.
    DIABETES, 2021, 70
  • [9] Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
    Nebojša Lalić
    Monika Russel-Szymczyk
    Marina Culic
    Christian Klyver Tikkanen
    Barrie Chubb
    Diabetes Therapy, 2018, 9 : 1201 - 1216
  • [10] Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
    Lalic, Nebojsa
    Russel-Szymczyk, Monika
    Culic, Marina
    Tikkanen, Christian Klyver
    Chubb, Barrie
    DIABETES THERAPY, 2018, 9 (03) : 1201 - 1216
12345